HIF-1α and mTOR: possible novel strategies of targeted therapies in p16-positive and -negative HNSCC
Background/Aim: Targeted therapy in head and neck squamous cell carcinoma (HNSCC) is limited. HIF-1α and mTOR are involved in the formation of local tumor progression and distant metastasis. The present study analyzed the influence of well-established tyrosine kinase inhibitors nilotinib, dasatinib,...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May-June 2018
|
| In: |
Cancer genomics & proteomics
Year: 2018, Jahrgang: 15, Heft: 3, Pages: 175-184 |
| ISSN: | 1790-6245 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: http://cgp.iiarjournals.org/content/15/3/175
|
| Verfasserangaben: | Benedikt Kramer, Max Polit, Richard Birk, Nicole Rotter and Christoph Aderhold |
| Zusammenfassung: | Background/Aim: Targeted therapy in head and neck squamous cell carcinoma (HNSCC) is limited. HIF-1α and mTOR are involved in the formation of local tumor progression and distant metastasis. The present study analyzed the influence of well-established tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on the expression of HIF-1α and mTOR in p16-positive and -negative squamous cancer cells (SCC) in vitro in order to develop novel strategies in the treatment of HNSCC. Materials and Methods: Expression of HIF-1α and mTOR was analyzed by using Sandwich-ELISA in p16-negative and p16-positive SCC after treatment with nilotinib, dasatinib, erlotinib and gefitinib (20 μmol/l, 24-96 h of incubation). Results: All substances significantly reduced mTOR expression in both, p16-negative and p16-positive SCC (p<0.05). HIF-1α expression was significantly reduced by all tested substances in p16-negative SCC. However, a statistically significant increase of HIF-1α was observed in p16-positive SCC. Conclusion: This is the first study to investigate the alteration of expression levels of HIF-1α and mTOR under selective tyrosine kinase inhibition in both p16-positive and -negative SCC. Our findings provide novel insights for a better understanding of HIF-1α and mTOR in the tumor biology of HNSCC and their interaction with selective small-molecule inhibitors. |
|---|---|
| Beschreibung: | Gesehen am 30.09.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1790-6245 |